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Type I interferon responses in rhesus macaques
prevent SIV infection and slow disease progression
Netanya G. Sandler1{, Steven E. Bosinger2,3, Jacob D. Estes4, Richard T. R. Zhu1, Gregory K. Tharp2,3, Eli Boritz1, Doron Levin5,
Sathi Wijeyesinghe1, Krystelle Nganou Makamdop1, Gregory Q. del Prete4, Brenna J. Hill1, J. Katherina Timmer1, Emma Reiss1,
Ganit Yarden5, Samuel Darko1, Eduardo Contijoch1, John Paul Todd6, Guido Silvestri2, Martha Nason7, Robert B. Norgren Jr8,
Brandon F. Keele4, Srinivas Rao6, Jerome A. Langer9, Jeffrey D. Lifson4, Gideon Schreiber5 & Daniel C. Douek1
Inflammation in HIV infection is predictive of non-AIDSmorbidity
anddeath1, higher set point plasmavirus load2 and virus acquisition3;
thus, therapeutic agents are in development to reduce its causes and
consequences. However, inflammation may simultaneously confer
both detrimental andbeneficial effects. This dichotomy is particularly
applicable to type I interferons (IFN-I)which,while contributing to
innate control of infection4–10, also provide target cells for the virus
during acute infection, impairCD4T-cell recovery, and are associated
withdiseaseprogression6,7,11–19.Herewemanipulated IFN-I signalling
in rhesus macaques (Macaca mulatta) during simian immunodefi-
ciency virus (SIV) transmission and acute infection with two comple-
mentary in vivo interventions. We show that blockade of the IFN-I
receptor caused reduced antiviral gene expression, increased SIV res-
ervoir size and accelerated CD4 T-cell depletion with progression to
AIDSdespite decreasedT-cell activation. In contrast, IFN-a2a admin-
istration initially upregulated expression of antiviral genes and pre-
vented systemic infection. However, continued IFN-a2a treatment
induced IFN-I desensitizationanddecreased antiviral gene expression,
enabling infection with increased SIV reservoir size and accelerated
CD4T-cell loss. Thus, the timing of IFN-induced innate responses in
acute SIV infection profoundly affects overall disease course and out-
weighs the detrimental consequences of increased immune activation.
Yet, the clinical consequences of manipulation of IFN signalling are
difficult to predict in vivo and therapeutic interventions in human
studies should be approached with caution.
Wedesigned andproduced an IFN-I receptor antagonist (IFN-1ant)
that blocks IFN-a2 antiviral and antiproliferative activity in vitro19. Six
rhesus macaques received 1mg of IFN-1ant daily for 4weeks follow-
ing intrarectal challengewith SIVMAC251 (dosage based onprevious dose–
response studies; Extended Data Fig. 1a–d); nine macaques received
saline (ExtendedData Fig. 1e). Initial assessment of in vivo effects revealed
delayed peakmRNAexpression ofMX1 andOAS2 in the IFN-1antmaca-
ques (Extended Data Fig. 2a, b), but peak expression levels did not differ
between cohorts.Whole-transcriptomesequencing revealed that express-
ionofmost interferon-stimulatedgenes (ISGs) inperipheralbloodmono-
nuclear cells (PBMCs)was significantly decreased at 7 days post-infection
(d.p.i.) in the IFN-1ant-treated compared to placebo-treated macaques
(Fig. 1a), including the antiviral genes APOBEC3G andMX2, those that
code for cyclic GMP-AMP synthase (cGAS) and tetherin4,5,20, and IRF7,
a master IFN-I signalling inducer21, indicating profound disruption of
IFN-I signalling (Fig. 1b). Most ISGs in the IFN-1ant group normalized
at 10and21d.p.i. andwereupregulatedat28and84d.p.i. (ExtendedData
Fig. 2c). Consistent with transcriptional data (Extended Data Fig. 2d, e),
APOBEC3G,TRIM5aandMX2proteinexpressionbyquantitative immu-
nohistochemistrywas significantly attenuated in lymphnodes at 4weeks
post-infection (w.p.i.) compared to placebo (Fig. 1c). Thus, IFN-1ant
treatment during acute SIV infection resulted in delayed and decreased
antiviral geneandproteinexpression inperipheralbloodand lymphnodes.
Consistentwith reduced antiviral gene expression, IFN-1antmacaques
had significantly higher plasma viral loads (pVLs) thanplacebomacaques
during acute infection (Fig. 2a) and after 20w.p.i. despite similar numbers
of transmitted/founder viruses (measured 10d.p.i., ExtendedData Fig. 8a).
Delayedpeak ISGexpression, however,was predictive ofhigherpVLs at
peak and 12w.p.i. and higher PBMC-associated SIV gagDNA levels at
28d.p.i. (ExtendedDataFig.2f–h).Additionally, thenumberof lymphnode
SIV RNA1 cells per mm2 as determined by in situ hybridization was sig-
nificantly higher inmacaques treatedwith IFN-1ant compared to placebo
during chronic infection (Fig. 2b). Thus, early IFN-I signallingwas critical
for early and long-term control of SIV replication and virus reservoir size.
Although both groups experienced a similar, significant decrease in
circulating CD4 T-cell frequency (Fig. 2c) and CD4/CD8 T-cell ratio
(ExtendedDataFig.3a)between0and12w.p.i., IFN-1antmacaquesexperi-
encedaprofounddeclinewith a lower lymphnodeCD4T-cell frequency
and CD4/CD8 T-cell ratio beyond 12w.p.i. (Fig. 2d and Extended Data
Fig. 3b). The frequency ofCCR51memoryCD4Tcells, potential targets
for infection, was significantly lower in blood in IFN-1ant-treated than
placebo-treated rhesus macaques through 12w.p.i. (Fig. 2e), and lymph
nodes at 4 and.12w.p.i. (Fig. 2f), suggesting depletion due to infection.
Circulating T-cell activation, reflected byHLA-DR1 andKi671memory
CD4 and CD8 T-cell frequencies, was not significantly different between
groups at 4 or.12w.p.i. (Supplementary Information). However, HLA-
DR1 and Ki671memory CD4 and CD8 T-cell frequencies were signifi-
cantly lower in the lymph nodes of IFN-1ant macaques than placebo at
.12w.p.i. (Extended Data Fig. 3c–f). Taken together, IFN-I signalling
blockade during acute SIV infection resulted in attenuated T-cell activa-
tion in lymphoid tissue yet accelerated CD4 T-cell depletion.
Clinical outcome ultimately gives the most comprehensive measure
ofdisease state.Consistentwithamedian life expectancyof1 year22, the six
placebo-treated macaques followed through 44w.p.i. (three were trans-
ferred to another study before 30w.p.i.) lived, but the IFN-1antmacaques
began dying of AIDS at 24w.p.i. and all were euthanized per protocol for
signs ofAIDSby30w.p.i. (Fig. 2g). Thus, blocking IFN-I signallingduring
only the first 4weeks of infection resulted in accelerated disease progres-
sion and death from AIDS.
Exploration of themolecularmechanismsunderlying the accelerated
diseaseprogressionbywhole-transcriptomesequencingrevealedstatistically
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significant enrichment of pathways regulating innate immunity, IFN-
I production and T- and B-lymphocyte activation (ExtendedData Fig.
4a–c) with significant downregulation of most genes in the IFN-1ant
groupat7d.p.i. compared toplacebo-treatedcontrols (Fig.1dandExtended
Data Fig. 2c). Relative to placebo, themost significantly perturbed path-
way in the IFN-1ant-treated animals consisted of pathogen-associated
pattern recognition receptor (PRR) signalling molecules (Fig. 1d and
ExtendedData Fig. 4a),with significant downregulation of several viral
PRRs (TLR3,TLR7,DDX58/RIG-I,MDA5/IFIH1) and theirdownstream
adaptors (TICAM1/TRIF) or transcription factors (IRF7) in IFN-1ant
macaques compared to placebo (ExtendedData Fig. 4c). Concordantly,
expression of the downstreammediators IL-6, TNF and IL-1b was sig-
nificantly reduced.
Consistentwith their responsiveness to IFN-I23, the frequencies of total
and cytotoxicCD161natural killer (NK) cellswere significantly lower in
the IFN-1antgroupthanplaceboat.12w.p.i., althoughtherewerenodifer-
ences at 4w.p.i. (ExtendedData Fig. 3g–i). However, we observed no sig-
nificant differences in phenotype, function or timing ofCD4 orCD8T-cell
responses (Extended Data Fig. 5 and Supplementary Information).
Collectively, these data suggest that IFN-I signalling early in SIV infec-
tion is critical for innate immune control of virus replication and that its
antagonism, even if only brief during the acute phase, results in decreased
virus control, accelerated CD4T-cell depletion and progression to AIDS.
Given these findings, wehypothesized that administering IFN-I could
improveSIVMAC251controldespite evidence suggesting that inflammation
exacerbates virus acquisition and disease progression1–3,13. Six macaques
received 6mg kg21 pegylated IFN-a2a dosed weekly, as determined in
prior studies24, starting 1weekbefore challenge and continued through
4weeks after systemic infection (defined as detectable pVL7 days post-
challenge).Macaques were followed until 12w.p.i. then euthanized per
protocol (ExtendedData Fig. 1e).Whereas all nine placebomacaqueswere
infected after the first intrarectal inoculation, IFN-a2a treatment signifi-
cantlydelayed systemic infection, necessitating two, three or five challenges
to infect these macaques (Fig. 3a), and significantly decreased the number
of transmitted/founder variants (Extended Data Fig. 8a). Themacaques
that required more challenges had fewer transmitted/founder variants
(Fig. 3b); however, the circulating viruses at peakviral load inbothgroups
were equally susceptible to in vitro IFNa inhibition (data not shown).
Thus, treatment with IFN-a2a during SIV challenge increased host res-
istance to systemic infection.
We assessedwhether ISGsmay have contributed to resistance to infec-
tion. We found thatMX1 and OAS2 gene expression detected by quant-
itative reverse transcriptionPCR(qRT–PCR) increasedafter one IFN-a2a
dose but decreased after repeated administration, suggesting an IFN-
desensitized state (Extended Data Fig. 6a–d) resulting in no significant
differences between treated andplacebogroups on the dayof infectious
challenge. Furthermore, IFN-a2a macaques had lower ISG expression
compared to placebo at 7 and 10 d.p.i., including those encoding cGAS,
APOBEC3G,MX2 and tetherin (Fig. 3c–f and ExtendedData Fig. 7a–b).
At 4w.p.i., after 6, 7 or 9 doses of IFN-a2a, lymph node TRIM5a protein
expression was significantly lower in the IFN-a2a group compared to
placebo (ExtendedDataFig. 8b).Toexplore the effects of IFN-a2aadmin-
istration on ISG expression further, we performed whole-transcriptome
sequencing on uninfected rhesus macaques administered pegylated IFN-
a2a for 3weeks. Seven days after one IFN-a2a dose, expression of virus
restriction factors including TRIM22, MX2 and IRF7 was increased in
PBMCs, lymph nodes and rectum (Extended Data Fig. 7c–h). However,
after 3doses these ISGs returned topre-treatment expression levels (MX2)
or lower (TRIM22 and IRF7), consistentwith the timingof infectionof the
SIV-challengedmacaques. (Extended Data Fig. 7c–h).We found no in
vitro IFN-neutralizing activity in the plasma at the time of infection to
explain the loss of exogenous IFN-a2a activity (Extended Data Fig. 6e
and Supplementary Information), suggesting that ISG downregulation
probably occurred as a result of intrinsic regulatorymechanisms. Indeed,
FOXO3a, a central regulator of IFN-I feedback25, was significantly upre-
gulated in the IFN-a2a compared to placebomacaques at 7 d.p.i. (Fig. 3g
and Extended Data Fig. 6g) and, concordantly, ISGs demonstrated to be
repressibly bound by FOXO3a (ref. 25) had lower expression at 7 d.p.i.
(ExtendedDataFig. 6h).Wealsoassessedabroadpanel of genespredicted
to be bound by FOXO3a (ref. 25) using gene-set enrichment analysis and
observed a significantly lower cumulative ranking of FOXO3a targets in
the 7d.p.i. IFN-a2a-treatedmacaque transcriptomedatawhencontrasted
to the 7 d.p.i. placebo data (Fig. 3h), suggesting increased FOXO3a-
mediated repression in the IFN-a2amacaques. Indeed, after 21 days of
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Figure 1 | IFN-1ant suppresses early antiviral responses. a, Expression of
ISGs in macaques treated with IFN-1ant (n5 6) or placebo saline (n5 9)
7 days after SIV infection. FPKM (log-transformed fragments per kilobase of
transcript per million fragments sequenced) reflects the relative abundance of
transcripts. P values indicate differentially expressed genes at 7 d.p.i.
b, Expression assessed by RNA sequencing (RNA-seq) of antiviral genes
APOBEC3G,MX2 and those that code for cGAS and tetherin in PBMCs before
and 7 days after SIV infection in macaques that received IFN-1ant (Ant, n5 6)
or placebo (Plac, n5 9) injections. Error bars indicate range. P values were
calculated by Mann–Whitney U test. c, APOBEC3G, TRIM5a and MX2
protein expression by immunohistochemistry of lymph nodes (LNs) at 4w.p.i.
in placebo (n5 6) and IFN-1ant (n5 6) macaques. Horizontal bars represent
median values. P values were calculated by Mann–Whitney U test. The left
panels are representative images of APOBEC3G staining from each group.
d, Expression of genes involved in pattern recognition receptor signalling of
IFN-1ant-treated (n5 6) macaques compared to placebo (n5 9). P values
represent the differential expression between IFN-1ant and placebo macaques
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IFN-a2a treatment in the unchallengedmacaques, increased FOXO3a
expression was associated with ISG downregulation (Extended Data
Fig. 6f). While these data do not exclude additional mechanisms, they
suggest that ISGdownregulation in the IFN-a2a-treatedmacaqueswas a
consequenceof endogenoushomeostatic control rather thanneutralization
of exogenous IFN-a2a.Thus, exogenous augmentationof IFN-I signalling
was associated with enhanced protection against SIV acquisition, but sus-
ceptibility to exacerbated systemic infection once ISG expression waned.
Given their roles in virus control, T andNK cells were evaluated. No
changes in SIV-specific CD4 or CD8 T-cell responses developed with
repeated challenges, suggesting that resistance to infection did not depend
on adequate T-cell responses (Supplementary Information). However,
higher circulatingCD561NK-cell frequencies after starting IFN-a2a pre-
dicted more challenges necessary for infection and were associated with
resistance to infection (Extended Data Fig. 8c). Once the CD561NK-cell
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frequency declined, the macaques became infected. In rectal biopsies at
28d.p.i., more resistantmacaques had higherCD161NK-cell frequencies
(ExtendedDataFig. 8d).Together, thesedata suggest that IFN-a2a-induced
innate immunity, rather thanT-cell responses, protectedagainstSIV infection.
Despite fewer transmitted/founder variants, pVLs did not differ sig-
nificantly between IFN-a2a andplacebo groups (ExtendedData Fig. 8e),
potentiallyobscuredby thevariabilityandsmallnumberofmacaques.PBMC-
associated SIV gagDNA levels, however, were significantly higher in the
IFN-a2a group than placebo at 10, 14 and 28 d.p.i. (Fig. 4a).While the
circulating CD4 T-cell frequency (Fig. 4c) and CD4/CD8 T-cell ratio
(Fig. 4d) declined between 0 and 4w.p.i. in both groups, the CD4/CD8
T-cell ratiowas significantly lower in the IFN-a2a group (basedon area
under the curve (AUC) (0–12w.p.i.)). The CCR51memoryCD4T-cell
frequency in blood was significantly lower in IFN-a2a than placebo
macaques during acute (AUC(0–4w.p.i.), Fig. 4e) and chronic infec-
tion (AUC(0–12w.p.i.)) and in lymphnodes at 4 (Fig. 4f) and 12w.p.i.,
although the frequencyofCD4Tcells andCD4/CD8T-cell ratio in lymph
nodes and jejunum were similar between groups at 4 and$12w.p.i.
(data not shown). Thus, SIV-infected IFN-a2a-treated macaques had
increasedCD4T-cell-associated virus load and greater CD4T-cell loss
with preferential depletion of the CCR51 subset.
We assessed whether increased immune activation was associated
with this CD4T-cell loss. The circulating Ki671memory CD4 andCD8
T-cell frequencieswere lower in the IFN-a2a compared toplacebogroup
during acute infection only (AUC(0–4w.p.i.)) with no differences in the
frequencies of HLA-DR1memory T cells (ExtendedData Fig. 9a–d). In
the lymphnodes, the frequencies ofKi671memoryCD4Tcells at 4w.p.i.
andHLA-DR1memoryCD4Tcells at$12w.p.i.were significantly lower
in the IFN-a2a than placebo group with no differences in CD8 T cells
(Extended Data Fig. 9e–h). Thus, the IFN-a2a macaques had similar
or less immune activation compared to placebo macaques.
We further explored the mechanisms underlying the increased cell-
associated SIV and CD4 T-cell depletion in IFN-a2a macaques using
whole-transcriptome sequencing of PBMCs. As with IFN-1ant, IFN-
a2a administration significantly affected the PRR signalling pathway
(Extended Data Fig. 10a). C1q, TLR3, TLR7 and RIG-I were downregu-
lated in the IFN-a2a macaques, yet expression of IL-6, TNF and IL-1b
was increased at 7 d.p.i. (Fig. 4b and ExtendedData Fig. 10b).Mediators
of stress responses and cell survival downstream of IL-6 signalling, such
asMAP2K3, andother anti-apoptotic genes suchasDIABLO andBCL2L1
were upregulated at 7 d.p.i. (Extended Data Fig. 10b, 10c), whereas
pro-apoptotic genes including CASP10were downregulated. Thus, early
IFN-a2a administration increased early expression of proinflammatory
cytokines despite decreased PRR expression and delayed induction of
apoptotic pathways.
Wenext assessedT- andNK-cell-mediated immunity. IFN-a2a-treated
macaqueshad intact andevenenhancedSIV-specificCD8T-cell responses
with no deficits in CD4 T-cell responses (Extended Data Fig. 8f–i and
Supplementary Information).Whereas therewere nodifferences at 4w.p.i.,
between 4 and 12w.p.i., the CD561 NK-cell frequency increased and
CD161NK-cell frequency decreased in the IFN-a2a but not the placebo
group.The frequencies ofCD161 (ExtendedDataFig. 8j),CD107a1 and
granzyme B1NK cells at 12w.p.i. were subsequently lower in the IFN-
a2a-treated macaques compared to placebo.
Taken together, these data show that despite initially increasing ISG
expression and conferring resistance to SIV infection, continued IFN-a2a
treatmentresulted inanIFN-desensitizedstate,withdecreasedantiviralgene
expression, increased susceptibility to infection, increased cell-associated
virus load and greater CD4 T-cell depletion compared to placebo.
Thus, both IFN-I receptor blockade and IFN-a2a administration
ultimately resulted in decreased and delayed IFN-I responses, the bio-
logical outcomes of which reveal a pivotal role for IFN-I signalling in
acute retroviral exposure in primates that overshadows the potential
harm of increased inflammation. That a delay of as few as 3 days in
antiviral gene expression resulted in accelerated disease progression
suggests that SIV disease course is determined very early and depends
upon the precise timing of peak antiviral activity. The observation of
shortened time-to-death despite the eventual normalization of ISG
expression during chronic infection clearly shows that a resurgence
of late antiviral activity cannot compensate for compromised early virus
control. Indeed, administration of IFN-a in chronicHIV infection has
given inconsistent results for virus load andCD4T-cell countswith no
effect on disease outcome7–9. An interesting parallel to our study was
recently described inmicewith chronic lymphocytic choriomeningitis
virus infectionwhere persistent IFN-I signalling exerts antiviral effects
but also leads to immune hyperactivation and suppression of antiviral
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Figure 4 | IFN-a2a accelerates disease progression. a, PBMC-associated SIV
gagDNAat 10, 14 and 28 d.p.i. in IFN-a2amacaques (IFN, n5 6) and placebo
(Plac, n5 6)macaques. LLQ indicates lower limit of quantification. Horizontal
bars represent median values. P values were calculated by Mann–Whitney
U test. b, Expression of differentially expressed genes involved in pattern
recognition receptor signalling. P values represent the comparison between
FPKMs of IFN-a2a (n5 6) and placebo (n5 9) macaques at 7 d.p.i.
c, Frequency of CD4 T cells in peripheral blood during acute and early SIV
infection in IFN-a2a (n5 6) and placebo (n5 9) macaques. Error bars
indicate range. Shading indicates treatment period. Red vertical line indicates
day 0 of systemic SIV infection. d, CD4/CD8 T-cell ratio in peripheral blood
during acute and early SIV infection in IFN-a2a (n5 6) and placebo (n5 9)
macaques. Error bars indicate range. Shading indicates treatment period. Red
vertical line indicates day 0 of systemic SIV infection. P value represents the
comparison between groups of the AUC (0-12 w.p.i.). e, Frequency of CCR51
memory CD4 T cells in peripheral blood in IFN-a2a (n5 6) and placebo
(n5 9) macaques. Error bars indicate range. Shading indicates treatment
period. Red vertical line indicates day 0 of systemic SIV infection. P values
represent the comparison between groups of the AUC (0-4 and 0-12 w.p.i.).
f, Frequency of CCR51 memory CD4 T cells in lymph nodes in IFN-a2a
(n5 6) and placebo (n5 9) macaques. Horizontal bars represent median
values. P values were calculated by Mann–Whitney U test. For all panels,
IFN-a2a-treatedmacaques are represented in green, placebo-treatedmacaques
in blue.
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T-cell responses14,15.Our findingsdiffer fromaprevious study that reported
unchanged virus burden with IFN-a2a administration during chronic
SIV infection24 and a study of IFN-a2b or the IFN-aB/D chimaera in
rhesusmacaques challenged intravenously with highly pathogenic SIV
DeltaB670 that showedno protection from infection but decreased peak
antigenaemia26. The initial protection from infection and decrease in
transmitted/founder variants observed in our study highlight the rectal
mucosa’s function as a barrier to SIV during transmission in the con-
text of ISG induction. It is tempting to speculate that administration of
IFN-a2a before SIV challenge also facilitated NK-cell activation and
recruitment to the rectumand contributed toprotection from infection27.
Given the relative IFN-I resistance of transmitted/founder viruses28,29 and
the induction of an IFN-desensitized state associated with the upregu-
lation of the IFN-I pathway repressor FOXO3a (ref. 25), our findings
add a cautionary note to adjuvanted HIV vaccines or other prevention
approaches that induce ISGs at mucosal surfaces. Furthermore, while
the rectum contains many resident target CD4 T cells30 that antiviral
mediators can protect, sites with few resident target cells, such as the
female genital tract16, may depend on IFN-I signalling for CD4 T-cell
recruitment and virus propagation. Thus, inflammationmight attenuate
transmission at the former site but exacerbate it at the latter3. In con-
clusion, disease progression inHIV infection emerges from the balance
between the beneficial antiviral effects of inflammation, its detrimental
systemic and immunologic effects, and its unique role of providing acti-
vatedCD4T-cell targets forHIV. Interferingwith onepart of this unstable
equilibriumhas unpredictable consequences. Thus, while there is good
reason to use both pro- and anti-inflammatory therapeutic approaches
in the treatmentandpreventionofHIVinfection, they shouldbeembarked
uponwith careful assessmentof the virological and immunological con-
sequences before widespread implementation.
Online ContentMethods, along with any additional Extended Data display items
andSourceData, are available in theonline versionof thepaper; referencesunique
to these sections appear only in the online paper.
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METHODS
Dose escalation study.We performed a dose escalation study in two rhesus maca-
ques with chronic SIVMAC251 infection and different frequencies of CD4 T cells and
CCR51 CD4 and CD8 T cells to maximize the likelihood of detecting a response.
IFN-1ant was dosed three times a week based on dosing of recombinant IFN-a2a
(Roferon-A, Roche, Switzerland) for hepatitis C infection.We administered 50mg of
IFN-1ant for oneweek, 200mg for oneweek, 500mg for oneweek and 800mg for one
week. Based on a dose-dependent increase in CD4 T-cell frequency and decrease in
the frequencies ofCCR51CD4andCCR51 andKi671CD8Tcells (ExtendedData
Fig. 1a–d), and because of ease of administration, we decided on 1mg of IFN-1ant.
Daily dosing was chosen as the effects appeared to be variable based on the time
since last dosing.
Macaques and experimental design. To examine the effects of blocking type I
IFN signalling, healthy, SIV-uninfectedMamuA012B082B172 adultMacacamulatta
received 1mg daily intramuscularly of the IFN-I receptor antagonist (IFN-1ant,
1mgml21,n56; synthesized as previously described19) or 1ml normal saline (n59)
by intramuscular injection for 4weeks (see Extended Data Fig. 1e). The macaques
were inoculated weekly, starting the first day of treatment, with 1ml of SIVMAC251 via
rectal challenge (1ml of a 1:25 dilution, stock 33108 SIV RNA copiesml21), up to
three times until infectionwas confirmed (SIV pVL.250 copiesml21). Bloodwas
sampled several times per week, and lymph node and jejunal biopsies were per-
formed before treatment and at the end of the 4-week period. All blood draws and
biopsies were performed before inoculation with SIVMAC251 and before any drug
administration on that day. The macaques were followed for up to 40w.p.i.
To examine the effect of exogenous IFN-I treatment, six healthy, SIV-uninfected
Mamu A012B082B172 adult macaques received 6mg kg21 pegylated IFN-a2a
(Pegasys, Genentech USA) intramuscularly weekly starting one week before the first
SIVMAC251 inoculation.Dosewas based onprior efficacy studies in rhesusmacaques24.
The macaques were challenged intrarectally weekly on the same day as, but before,
IFN-a2a administration, with the same high-dose SIVMAC251 inoculation as the IFN-
1ant and placebo macaques, until infection was confirmed. All blood draws and
biopsies were performed before inoculation with SIVMAC251 and before any drug
administration on that day. The macaques were followed for a total of 12weeks
after infection and then euthanized per protocol. To examine the effect of exogen-
ous IFN-I treatment in the absence of SIV infection, three healthy, SIV-uninfected
Mamu A012B082B172 adult macaques received 6 mgkg21 pegylated IFN-a2a
(Pegasys,GenentechUSA) intramuscularlyweekly for 3weeks. Bloodwas sampled
twice weekly starting 1 week before IFN-a2a treatment through to 1 week after the
last dose. The lymph node, jejunum and rectum were biopsied before IFN-a2a
treatment, 1 week after the first dose and 1 week after the last dose.
All macaques were housed at Bioqual, Inc., and assigned randomly to treatment
or placebo arms. TRIMCyp, the fusion protein derived from TRIM5 and cyclo-
philin A, was present in 1 placebo macaque, 2 IFN-1ant macaques and 0 IFN-a2a
macaques. OneTRIM5a SPRYdeletionwas present in 4 placebomacaques, 3 IFN-
1antmacaques and1 IFN-a2amacaque (themacaque that required 5 challenges to
become systemically infected) and two TRIM5a SPRY deletions in 2 IFN-1ant
macaques. There was no significant difference in genotype distribution between
placebo and IFN-1antmacaques or between placebo and IFN-a2amacaques based
on Fisher’s test. Based on availability, the 6 IFN-1ant macaques and 9 placebo
macaques weremale and ages 4 to 7 years, and the 6 IFN-a2amacaques were female
with ages 9 to 15 years. The Vaccine Research Center Animal Care and Use Com-
mittee approved all study protocols and procedures.
Samples. Blood was collected in EDTA tubes. Plasma was collected and PBMCs
were isolated by Ficoll density centrifugation. All of the jejunum and half the lymph
node biopsy tissues and half of every tissue collected at necropsy were placed in
RPMIwith 10% fetal bovine serum (FBS) and transported onwet ice. The remain-
ing tissues were placed in 4% paraformaldehyde and kept at room temperature
overnight before being transferred to 80% ethanol and stored at 4 uC. Tissues were
subsequently paraffin-embedded for in situ hybridization and immunohistochem-
istry. Intestinal samples were incubated with RPMI1 collagenase D (1mgml21)
(Roche) 1 Penicillin-Streptomycin-Glutamine (Gibco) at 37 uC for 30min and
then passed through a 70mm filter. Lymph node samples were passed through a
70mm filter to remove debris. Cells isolated from both peripheral blood and tissues
were either stained for flow cytometry or cryopreserved.
Flow cytometry. Cellular activation and cell cycle entry were assessed by flow
cytometry. PBMCs and cells from the jejunum and lymph nodeswere stainedwith
Aqua LIVE/DEAD Fixable Dead Cell Stain and antibodies to the following: CD4
Qd605,CD8Qd655 (Invitrogen);CD3APC-Cy7,CD95PE-Cy5,CD14Pacific Blue,
CCR5PE,CCR7PE-Cy7,Ki67FITC(BDBiosciences);CD28ECD(BeckmanCoulter);
and HLA-DR Alexa 700PE (BD Biosciences, in-house conjugate). Cells were per-
meabilized using a Cytofix/Cytoperm kit (BD Biosciences) for Ki67 detection and
fixed with 1% formaldehyde (Tousimis).
To assess antigen-specific responses andNK cell subsets, cryopreserved PBMCs
were stimulated for 6 h at 37 uC with SIV Gag/Env/Pol peptide pool (2mgml21)
in the presence of CD28 and CD49d (BD Biosciences) and brefeldin A (Sigma,
10mgml21). Cells were stained with Aqua LIVE/DEAD Fixable Dead Cell Stain
(Invitrogen) and antibodies to the following: CD3 APC-Cy7, CD14 Pacific Blue,
IFN-cCy7PE, TNFAPC,CD107a FITC (BDBiosciences); GranzymeBPE (Caltag);
CD4Qd605,CD8Qd655 (Invitrogen);CD16Ax594,CD20Ax700PE,CD56Cy5PE,
Perforin Ax680 (in-house conjugates, BD Biosciences). Cells were permeabilized
using a Cytofix/Cytoperm kit (BD Biosciences) for intracellular cytokine detection
and fixed with 1% formaldehyde (Tousimis).
To evaluate cellular exhaustion, cryopreserved PBMCs were stimulated for 6 h
at 37 uCwith SIVGag/Env/Pol peptide pool (2mgml21) in the presence of brefeldin
A (10mgml21). Cells were stained with Aqua LIVE/DEAD Fixable Dead Cell Stain
(Invitrogen) and antibodies to the following: CD3 APC-Cy7, CD95 Cy5PE, IFN-c
FITC, TNF APC, Bcl-2 PE (BD Biosciences); CD28 ECD (Beckman Coulter); ICOS
Pacific Blue (Biolegend); CD4Qd605, CD8Qd655, StreptavidinCy7PE (Invitrogen);
PD-1 biotinylated (R&DSystems).Cellswere permeabilized using aCytofix/Cytoperm
kit (BD Biosciences) for intracellular cytokine detection and fixed with 1% form-
aldehyde (Tousimis).
Transmitted/founder variant characterization. The number of transmitted/
founder variants were characterized blindly, as previously described28, and depos-
ited in GenBank under accession numbers KJ201031 to KJ201503.
Determination of susceptibility of circulating SIV to IFN-a. Freshly isolated,
CD8-depleted PBMCs from naive rhesus macaque donors were stimulated for
3 days with 5mgml21 PHAand 100Uml21 IL-2 in RPMI supplementedwith 10%
FBS, 2mML-glutamine, 100Uml21penicillin and100mgml21 streptomycin (RPMI-
Complete). Target cells were re-suspended at 106 cellsml21 in RPMI-Complete con-
taining various concentrations of recombinanthuman IFN-a (PBL InterferonSource)
and incubated at 37 uC for 4h. IFN-a-containing culture supernatants were collected
and stored at 37 uC. Target cells were split into duplicate cultures and spinoculated for
2h at 800g with diluted, equivalent input amounts of SIV from plasma from 14 to
18d.p.i. from IFN-a2a or placebo macaques. Cells were washed and re-suspended in
matched, stored IFN-a containing supernatants supplemented with 100Uml21
IL-2. After incubation at 37 uC for 7 days, cell-free culture supernatants were col-
lected and a SIV p27 antigen capture assay was used to detect the presence of viral
p27 antigen according to the manufacturer’s instructions (ABL).
Binding andneutralizing antibody assays. IFN-binding antibodies were assessed
as previously described31. Toevaluate for neutralizing antibodies,A549 cells (American
TypeCulture Collection,Manassas, VA)were seeded at 13104 per well in RPMIwith
2% FBS and 2mM L-glutamine and incubated for 24h. For the standard curve, IFN-
a2b (Hoffman La Roche, Nutley, NJ) was added to cells in twofold serial dilution from
5 IUml21 to 0.04 IUml21. For measurement of IFN-a2b-neutralizing antibodies
in plasma, IFN-a2bwas added at a concentration of 0.5 IUml21 alongwith 160-fold
diluted plasma. Control wells received medium only or 5 IUml21 IFN-a2b and
13.1mgml21 of a control neutralizing antibody. After an additional 24h, the media
was removed and replaced with RPMI 1640 containing 2% FBS, 2mM L-glutamine
containing encephalomyocarditis virus (EMCV, American Type Culture Collection,
Manassas,VA)at amultiplicityof infectionof 0.5.Cellswere stainedwith crystal violet
at 52 h and assessed for cytopathic effect asmeasured by optical density at 570 nm.
Quantitative RT–PCR.RNAwas extracted fromPBMCs preserved in TRIzol (Life
Technologies) or from thawed cryopreserved PBMCs by RNAzol RT (Molecular
Research Center, Inc.) according to the manufacturers’ instructions. Purified RNA
was added directly to a one-step quantitative RT–PCR reaction containing iScript
RT-iTaqTaq enzymemix (BioRad).MX1,OAS2 andb2microglobulinwere labelled
with a 59 FAM reporter and 39 BHQ1 quencher (Biosearch Technologies). We used
the following oligonucleotide sequences: MX1 F AGGAGTTGCCCTTCCCAGA,
MX1 R CCTCTGAAGCATCCGAAATC,MX1 P TGACCAGATGCCCGCTGGT
G;OAS2FCAGTCCTGGTGAGTTTGCAGT,OAS2RCAGCGAGGGTAAATCC
TTGA, OAS2 P GCACTGGCATCAACAGTGCCAGA.
MX1 andOAS2 forward and reverse primerswere used at 500nM, andprobes at
200nM. Samples were run on an Applied Biosystems Sequence Detection System
7900HT (ABI). Expression levels ofMX1 andOAS2were normalized to b2micro-
globulin and calculated based on the DDCT method.
Transcriptomeanalysis.TotalRNAwaspreparedasdescribedabove.Polyadenylated
transcripts were purified on oligo-dTmagnetic beads, fragmented, reverse transcribed
using randomhexamers and incorporated into barcoded cDNA libraries based on the
IlluminaTruSeqplatform. Librarieswere validated bymicroelectrophoresis, quan-
tified, pooled and clustered on Illumina TruSeq v2 flowcells. Clustered flowcells
were sequenced on an Illumina HiSeq 2000 in 100-base single-read reactions.
New rhesus macaque genome. RNA-Seq data were analysed by alignment to a pro-
visional assembly (depositedunderBioProjectaccessionPRJNA214746)andannotation
of a new IndianMacaca mulatta genome (data provided by R.B.N., University of
Nebraska Medical Center and A. Zimin, University of Maryland). Comparison of
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RNA-seq data generated using the v.4 assembly demonstrated a greater absolute
number of mapping reads, higher proportion of mapped reads per sample than to
the hg19 RefSeq or RheMac2 assembly (Supplementary Fig. 1 and Supplementary
Information).
RNA-seq data analysis. RNA-seq data were submitted to The Gene Expression
Omnibus (GEO) repository at the National Center for Biotechnology Information
(NCBI). RNA-seq data were aligned to a provisional assembly of Indian Macaca
mulatta (MuSuRCA rhesus assembly v.4) using STAR version 2.3.0e32; parameters
were set using the annotation as a splice junction reference, un-annotated non-
canonical splice junction mappings and non-unique mappings were removed from
downstream analysis. Transcripts were annotated using the provisional UNMC
annotation v4.12. Transcript assembly, abundance estimates and differential expres-
sionanalysiswereperformedusingCufflinksv2.1.1andCuffdiff33. Sampleswith,49%
mapped reads or exhibiting considerable 39 or 59 bias were excluded from further
analysis. To reduce normalization bias due to varying read depths, samples were
analysed in two separate groups: group 1 comprised 166 samples and contained the
samples fromPBMCs from the placebo1SIV, IFN-1ant1SIV, and pegylated IFN-
a2a-treated1SIVanimals, and fromsamples for the analysis of PBMCs,LNCD4T
cells and rectal biopsies of uninfected, IFN-a2a-treated animals; the average num-
ber ofmapped reads was 12,188,890 (range: 3,237,374–87,371,564). Group 2 com-
prised the lymph node CD4 T cells from the three SIV-infected groups consisting
of 37 samples; the averagemapped read count for this groupwas 4,898,448 (range:
1,173,455–19,310,483).Differentially expressedgenesweredefinedbypair-wise com-
parison of each time point to the Day 0 baseline. We included genes that had any
acute time point (0 vs 7, 10, 21, 28) that was significantly differentially expressed by
a fixed discovery rate-correctedP value (q value), 0.05. Differential gene lists were
uploaded to Ingenuity Pathway Analysis software (v1.0 Ingenuity Systems, http://
www.ingenuity.com/) and pathways with significant enrichment by Fisher’s exact
test and the Benjamini–Hochberg multiple testing correction were identified. Heat
maps and other visualization were generated using Partek Genomics Suite v6.6.
Gene-set enrichment analysis (GSEA). GSEA was performed using the desktop
module available from the Broad Institute (http://www.broadinstitute.org/gsea/).
FPKMs for samples fromthe IFN-a2a andplacebogroups at 7 d.p.i.werepre-filtered
to remove transcriptswith insufficient read coverage, and thenwere rankedusing the
signal-to-noise statistic. The gene-set was comprised of genes determined to be
upregulated in unstimulatedFOXO32/2macrophages relative tomacrophages from
control mice25. Significance was estimated using gene-set permutation.
SIV in situ hybridization, immunohistochemistry and quantitative image
analysis. SIV in situ hybridization was performed as previously described34. Immu-
nohistochemistry for rabbit polyclonal anti-APOBEC3G (Prestige Antibodies
Powered byAtlasAntibodiesHPA001812; Sigma-Aldrich), TRIM5a (PrestigeAnti-
bodies Powered byAtlas AntibodiesHPA023422; Sigma-Aldrich) andMX2 (Prestige
Antibodies Powered by Atlas Antibodies HPA030235; Sigma-Aldrich) were per-
formed using a biotin-free polymer approach (Rabbit Polink-2, Golden Bridge
International, Inc.) on 5mm tissue sections mounted on glass slides, which were
dewaxed and rehydrated with double-distilled H2O. Antigen retrieval was per-
formed by heating sections in 0.01% citraconic anhydride containing 0.05%Tween-
20 in a pressure cooker set at 122 uC for 30 s. Slides were rinsed in ddH2O, incubated
with blocking buffer (TBS containing 0.25% casein) and incubated with diluted
rabbit anti-APOBEC3G, rabbit anti-TRIM5a or rabbit anti-MX2 in blocking buffer
overnight at 4 uC. Tissue sections were rinsed in wash buffer (13TBS containing
0.05% Tween-20) for 10min followed by an endogenous peroxidase blocking step
using 1.5% (v/v) H2O2 in TBS (pH7.4) for 10min and placed in wash buffer. Slides
were incubated with rabbit Polink-2 HRP polymer-staining system (Golden Bridge
International, Inc.) according to manufacturer’s recommendations (20–30 min at
room temperature) then rinsed in wash buffer. Tissue sections were developed with
Impact 3,39-diaminobenzidine (Vector Laboratories), counterstained with haema-
toxylin andmounted inPermount (Fisher Scientific). All stained slideswere scanned
at highmagnification (3 200) using the ScanScopeCSSystem(AperioTechnologies,
Inc.) yielding high-resolution digital scans of the entire tissue section. Regions of
interest of defined area (ROIs; 500mm2) were saved on the digital image using the
Aperio rectangle tool (representing nearly the entire lymph node section) and high-
resolution images were extracted from the ROIs of each whole-tissue scan. The per
cent area of the lymph node (all anatomical compartments were included) that
stained for APOBEC3G, TRIM5a and MX2 were quantified under blind analysis
using Photoshop CS5 and Fovea tools.
Statistical methods. Based on our previous data of rhesus macaques with acute
SIV infection, the standard deviation for SIV RNA levels is 0.53 106 copiesml21.
Using this value, 6macaques in the IFN-1ant or IFN-a2a group and 9macaques in
the placebo group would give us 80% power to detect a 0.83 106 copiesml21
difference in SIV RNA levels between IFN-1ant or IFN-a2a and placebo groups.
Macaques were assigned to their respective groups randomly. Experiments, except
as noted above, were not performed blindly. All replicates are biological replicates.
Each experiment was performed once. Comparisons between groups at singular
time points were performed with the Mann–Whitney U test, comparisons within
groups with theWilcoxonmatched-pairs signed rank test, survival curve compar-
isons for per cent survival (IFN-1ant) and per cent uninfected (IFN-a2a) with the
log-rank (Mantel-Cox) test and correlations with Spearman coefficient, all using
GraphPad Prism v5.0d. Comparisons of AUCs were performed using linear
regression analysis adjusting for baseline values on JMP v10.
31. Vanderford, T. H. et al. Treatment of SIV-infected sooty mangabeys with a type-I
IFN agonist results in decreased virus replication without inducing
hyperimmune activation. Blood 119, 5750–5757 (2012).
32. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29,
15–21 (2013).
33. Trapnell, C. et al. Differential analysis of gene regulation at transcript resolution
with RNA-seq. Nature Biotechnol. 31, 46–53 (2013).
34. Brenchley, J.M.et al.Differential infectionpatternsofCD41Tcells and lymphoid
tissue viral burden distinguish progressive and nonprogressive lentiviral
infections. Blood 120, 4172–4181 (2012).
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Extended Data Figure 1 | Dose escalation study for IFN-1ant and
experimental schema. a–d, Effects of three times weekly IFN-1ant dosing on
the frequency of CD4 T cells (a), CCR51 CD4 T cells (b), CCR51 CD8 T cells
(c) and Ki671 CD8 T cells (d) in 2 rhesus macaques. Dose was 50mg in week 1,
200mg in week 2, 500mg in week 3 and 800mg in week 4. Vertical dotted lines
indicate the days a new dose was started. Black lines connect time points 4 days
after the first dose. Grey shading indicates treatment period. e, Six macaques
received 4weeks of IFN-1ant intramuscularly starting at day 0 and were
challenged intrarectally with 1ml of a 1:25 dilution of SIVMAC251 (stock
concentration 33 108 SIV RNAcopiesml21) at day 0 and followed until
developing end-stage AIDS. Nine macaques were treated with 4weeks of
placebo saline intramuscularly starting at day 0 and challenged intrarectally
with SIVMAC251 at day 0 and followed. Six macaques were injected weekly with
IFN-a2a starting 1week before the first challenge and through 4w.p.i.
Macaques required 2, 3 or 5 challenges to acquire systemic infection. Thus,
macaques received 6, 7 or 9 doses of IFN-a2a. Macaques were necropsied at
12w.p.i. per protocol.
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Extended Data Figure 2 | Effects of IFN-1ant on IFN-stimulated genes and
virus burden. a, b,MX1 (a) and OAS2 (b) expression by qRT–PCR during
acute SIV infection in IFN-1ant (red, n5 6) and placebo (blue, n5 9)
macaques. P values were calculated by Mann–Whitney U test. c, ISGs in
PBMCs in IFN-1ant and placebomacaques. P values represent the comparison
between IFN-1ant (n5 6) and placebo (n5 9) macaque FPKMs at 7 d.p.i.
d, e, SAMHD1 (d) and APOBEC3G (e) expression in the lymph nodes in
IFN-1ant (n5 6) and placebo (n5 9) macaques. P values were calculated by
Mann–Whitney U test. f, g, Plasma SIV RNA levels at 12w.p.i. (f) or at peak
(g) stratified by the day thatMX1 or OAS2 expression peaked in PBMCs in
IFN-1ant (n5 6) and placebo (n5 9) macaques. VL, viral load. P values were
calculated by Mann–Whitney U test. h, SIV gag levels in PBMCs stratified
by the day thatMX1 orOAS2 expression peaked in PBMCs in IFN-1ant (n5 6)
and placebo (n5 6) macaques. P values were calculated by Mann–Whitney U
test. For all panels, IFN-1ant-treated macaques are represented in red,
placebo-treated macaques in blue.
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Extended Data Figure 3 | Effects of IFN-1ant on CD4 T cells and on
immune activation. a, b, CD4/CD8 T-cell ratio in peripheral blood (a) and
lymph node (LN) (b) in IFN-1ant (Ant, n5 6) and placebo (Plac, n5 9)
macaques. Shading indicates treatment period. Error bars indicate range. Red
vertical line indicates day 0 of systemic SIV infection. For all panels, horizontal
bars indicate median values, and P values at different time points within
treatment groups were calculated by Wilcoxon matched pairs signed rank test
and between groups by Mann–Whitney U test. c–f, T-cell activation in lymph
nodes (c–f) in CD4 (c, d) and CD8 (e, f) T cells as represented by the frequency
of Ki671 (c, e) orHLA-DR1 (d, f) cells in IFN-1ant (n5 6) and placebo (n5 9)
macaques. g, Frequency of circulating CD161 or CD561CD32CD142 NK
cells in IFN-1ant (n5 6) and placebo (n5 9) macaques. h, Frequency of
circulatingCD161NKcells in IFN-1ant (n5 6) and placebo (n5 9)macaques.
i, Frequency of circulating CD561 NK cells in IFN-1ant (n5 6) and placebo
(n5 9) macaques. For all panels, IFN-1ant-treated macaques are represented
in red, placebo-treated macaques in blue.
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Extended Data Figure 4 | IFN-1ant alters innate and adaptive immune
signalling. a, Selected pathways significantly affected by IFN-I blockade.
P values were calculated by Fisher’s exact test with the Benjamini–Hochberg
multiple testing correction. b, Expression of genes involved in pattern
recognition receptor signalling of IFN-1ant-treated macaques (n5 6)
compared to placebo (n5 9) at 7 d.p.i. Upregulation compared to pre-infection
is represented by red, no change by white, downregulation by blue. P values
represent the comparison between IFN-1ant and placebo macaques at 7 d.p.i.
c, Selected genes in pattern recognition receptor signalling pathways.
Upregulation at 7 d.p.i. is represented by red, downregulation by green.
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Extended Data Figure 5 | Effects of IFN-1ant on T-cell function and
phenotype. a–e, SIV-specific responses in peripheral blood at 4 and.12w.p.i.
in IFN-1ant (Ant, n5 6) and placebo (Plac, n5 6) macaques by frequency of
IFN-c1 (a), TNF1 (b), perforin1 (c), granzyme B1 (d) andCD1071 (e) CD8 T
cells. T-cell exhaustion in peripheral blood and lymph nodes (LN) at.16w.p.i.
based on frequency of PD-11CD4 (f) and CD8 (h) T cells and ICOS1 (g) CD8
T cells. For all panels, P values at different time points within treatment groups
were calculated by Wilcoxon matched pairs signed rank test and between
groups by Mann–Whitney U test. IFN-1ant-treated macaques are represented
in red, placebo-treated macaques in blue.
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Extended Data Figure 6 | IFN-a2a treatment transiently induces ISGs and
subsequently induces the IFN-repressor FOXO3a but does not induce
neutralizing anti-IFN antibodies. a–d,MX1 (a, c) andOAS2 (b, d) expression
during the duration of IFN-a2a treatment in the IFN-a2a group alone
(a, b) and during infection in the IFN-a2a (n5 6) and placebo (n5 9) groups
(c, d). P values were calculated by Wilcoxon matched pairs signed rank test.
e, Percentage of in vitro IFNantiviral activity inhibited byplasma from IFN-a2a
(n5 6) and placebo (n5 3) macaques. f, Expression of FOXO3a and
FOXO3a-boundgenes in SIV-uninfectedmacaques (n53) treatedwith21daysof
IFN-a2a. Large circles indicate statistically significant (P,0.05) changes from
pre-IFN-a2a treatment calculated by Wilcoxon matched pairs signed rank test.
Small circles indicate no statistically significant change from pre-IFN-a2a
treatment.g, Expressionof IFN-a-regulatorygenes in IFN-a2a (n56) andplacebo
(n59)macaques. P values represent the comparison between FPKMs of IFN-a2a
(n56) and placebo (n59) macaques at 7d.p.i. h, Expression of FOXO3a-bound
genes in IFN-a2a (green, n56) and placebo (blue, n59) macaques at 7 d.p.i.
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Extended Data Figure 7 | Effects of IFN-a2a on IFN-stimulated and
antiviral genes. a, ISGs in PBMCs in IFN-a2a (n5 6) and placebo (n5 9)
macaques. Red indicates upregulation, yellow indicates no change and blue
indicates downregulation relative to pre-infection. b, Expression of ISGs in
macaques treated with IFN-a2a (n5 6) or placebo (n5 9). P values indicate
differentially expressed genes at 10 d.p.i. c–h, Expression of TRIM22
(c, d),MX2 (e, f) and IRF7 (g, h) in SIV-uninfected macaques (n5 3) treated
with weekly IFN-a2a for 3weeks in PBMCs (c, e, g) and lymph nodes and
rectum (d, f, h). Day 0 reflects baseline. Numbers indicate days since first IFN-
a2a administration. Error bars indicate range. P values were calculated by
Wilcoxon matched pairs signed rank test.
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Extended Data Figure 8 | Effects of IFN-a2a on SIV control. a, Number
of transmitted/founder (T/F) variants in placebo (n5 9), IFN-1ant (n5 6)
and IFN-a2a (n5 6) macaques. P value was calculated by Mann–Whitney
U test. b, Antiviral protein production in lymph nodes (LN) by
immunohistochemistry at 4w.p.i. in IFN-a2a (n5 6) and placebo (n5 6)
macaques. P value was calculated byMann–WhitneyU test. c, CD561NK-cell
frequency on the day of challenge stratified by whether the macaque resisted
or was susceptible to systemic infection that day. Each IFN-a2a macaque
(n5 6) is indicated by a different colour. Circles indicate that themacaque was
resistant to infection with the next challenge and triangles indicate that the
macaque was susceptible to infection with the next challenge. P value was
calculated by Mann–Whitney U test. d, Correlation between the number of
challenges required to achieve systemic infection and rectal CD161 NK-cell
frequency in each macaque (n5 6) at 4w.p.i. r indicates the Spearman’s rank
correlation coefficient. P value indicates the significance of the correlation.
e, Plasma SIVRNA levels inmacaques treated with IFN-a2a (n5 6) or placebo
(n5 9) saline. Shading reflects treatment period. Red vertical line indicates day
0 of systemic SIV infection. f–i, Frequency of IFN-c1 (f), TNF1 (g), granzyme
B1 (h) and perforin1 (i) CD8T cells at 4 and$12w.p.i. in IFN-a2a (n5 6) and
placebo (n5 6) macaques. j, Frequency of circulating CD161CD562 NK cells
in IFN-a2a (n5 6) and placebo (n5 9) macaques. P values at different time
points within treatment groups were calculated by Wilcoxon matched pairs
signed rank test and between groups by Mann–Whitney U test.
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Extended Data Figure 9 | Effects of IFN-a2a on T-cell activation.
a–h, Frequency of peripheral blood (a–d) and lymph node (LN) (e–h) CD4
(a, c, e, g) and CD8 (b, d, f, h) memory T cells expressingHLA-DR (a, b, e, f) or
Ki67 (c, d, g, h) in IFN-a2a (IFN, n5 6) and placebo (Plac, n5 9) macaques.
Shading indicates treatment period. Error bars indicate range. a–d, Red vertical
line indicates day 0 of systemic SIV infection. P values represent the
comparison between groups of the AUC (0-4 w.p.i.). e–h, Horizontal bars
indicate median values. P values were calculated by Mann–Whitney U test.
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ExtendedData Figure 10 | Effects of IFN-a2aongene expression. a, Selected
pathways significantly affected by IFN-a2a treatment. P values were
calculated by Fisher’s exact test with the Benjamini–Hochberg multiple testing
correction. b, Expression of genes downstream of IL-6 signalling. Upregulation
relative to before IFN-a2a or placebo treatment and SIV infection is
represented by red, no change by white, downregulation by blue. P values
represent the comparison between IFN-a2a (n5 6) and placebo (n5 9)
macaques at 7 d.p.i. c, Selected genes in apoptosis signalling pathways.
Significant upregulation at 7 d.p.i. is represented by red, downregulation
by green.
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